Vera Therapeutics, Inc. (VERA) 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Vera Therapeutics, Inc. (“Vera” or the “Company”) (NASDAQ: VERA). Investors who purchased Vera securities are encouraged to obtain additional information and assist the investigation.       

The investigation concerns whether Vera has violated federal securities laws.

On January 3, 2023, Vera issued a press release announcing what it characterized as “positive topline results” in its Phase 2b ORIGIN clinical trial of atacicept for the treatment of immunoglobulin A nephropathy.  Although Vera’s product candidate met its primary endpoint, analysts noted that the Phase 2b data would need to be replicated in a pivotal trial in order to secure regulatory approval and that other competing drugs in development might be more effective than atacicept.  Accordingly, following the release of the Phase 2b data, Wedbush downgraded Vera to neutral from outperform.  On this news, Vera’s stock price fell $11.84 per share, or 64.7%, to close at $6.46 per share on January 4, 2023.

If you are aware of any facts relating to this investigation or purchased Vera shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.